Last reviewed · How we verify
Ginkgo Biloba Extract 761 — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Ginkgo Biloba Extract 761 (Ginkgo Biloba Extract 761) — Dongzhimen Hospital, Beijing.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ginkgo Biloba Extract 761 TARGET | Ginkgo Biloba Extract 761 | Dongzhimen Hospital, Beijing | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ginkgo Biloba Extract 761 CI watch — RSS
- Ginkgo Biloba Extract 761 CI watch — Atom
- Ginkgo Biloba Extract 761 CI watch — JSON
- Ginkgo Biloba Extract 761 alone — RSS
Cite this brief
Drug Landscape (2026). Ginkgo Biloba Extract 761 — Competitive Intelligence Brief. https://druglandscape.com/ci/ginkgo-biloba-extract-761. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab